Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions

Sacubitril/valsartan is a new medication approved for the treatment of heart failure with reduced ejection fraction. While the drug failed to meet the primary endpoint in patients with heart failure with preserved ejection fraction in the PARAGON-HF trial, improvements were noted in several secondar...

Descripción completa

Detalles Bibliográficos
Autores principales: Galo, Jason, Celli, Diego, Colombo, Rosario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561468/
https://www.ncbi.nlm.nih.gov/pubmed/33063249
http://dx.doi.org/10.1007/s40256-020-00445-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561468/
https://www.ncbi.nlm.nih.gov/pubmed/33063249
http://dx.doi.org/10.1007/s40256-020-00445-7

Ejemplares similares